Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib in Advanced ROS1-positive NSCLC After TKI Failure
NCT04621188Phase 2Active, not recruiting
- Sponsor
- IFCT
- Start
- Mar 2021
- Primary completion
- Feb 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by IFCT. Primary endpoint: Objective Response Rate at 8 weeks. Started Mar 2021; status: active, not recruiting.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04621188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04621188.